Preanalytical influences in clinical proteomic studies: Raising awareness of fundamental issues in sample banking

Clinical Chemistry

Volumn 54, Issue 1, 2008, Pages 6-7

  Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

AWARENESS; CANCER RESEARCH; CLINICAL CHEMISTRY; CLINICAL PRACTICE; EDITORIAL; HOSPITAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEOMICS; STORAGE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TEMPERATURE;

ALGORITHMS; BIAS (EPIDEMIOLOGY); BLOOD SPECIMEN COLLECTION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 38749086467     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.097667     Document Type: Editorial

References (13)

1. Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22.
2. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 2005;4:1441-4.
3. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature (Lond) Biotechnol 2006;24:971-83.
4. Zolg W. The proteomic search for diagnostic biomarkers. Mol Cell Proteomics 2006;5:1720-6.
5. Rai AJ. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays. Expert Rev Mol Diagn 2007;7:545-53.
6. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, et al. Analytical validation of serum proteomic profiling for diagnosis of PCa: sources of sample bias. Clin Chem 2008;54:44-52.
7. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, et al. SELDI-TOF-MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60.
8. Semmes OJ, Feng Z, Adam B-L, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I, assessment of platform reproducibility. Clin Chem 2005;51:102-12.
9. Diamandis EP. Oncopeptidonics: a useful approach for cancer diagnostics? Clin Chem 2007;53:1004-6.
10. Ransohoff DF. Bias as a threat to validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
11. Ferguson RE, Hochstrasser DF, Banks RE. Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clin Appl 2007;1:739-46.
12. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5.
13. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-56.